Category Archives: Science: Biology

Cutting edge research is happening on a daily basis in our modern world, Keep up to date with our Press Release services.

Protein Metrics Launches Byosphere™ LC/MS Enterprise Platform


Biotherapeutic mass spectrometry analysis software

Byosphere Enterprise LC/MS Platform

Byosphere solves an essential problem for biotherapeutic research, development, and production.

Protein Metrics Inc., a leading provider of desktop mass spectrometry software for protein characterization, announced today the launch of Byosphere™ Enterprise Platform that combines biotherapeutic mass spec data, analysis, and reporting in one environment.

“Byosphere solves an essential problem because typical tools such as ELNs and LIMs cannot handle large, data-rich LC/MS files,” said Eric Carlson, Ph.D., President and CEO of Protein Metrics. “LC/MS data produces some of the most valuable data possible for biotherapeutic research, development, and production. Byosphere will let organizations curate, interrogate, and share that information swiftly and easily for better decision making in less time.”

Byosphere includes Protein Metrics’ leading desktop software, Byos®, which has been adopted by hundreds of organizations worldwide.

The new platform is already implemented with world-leading biotherapeutic developers. Deployable on premise or in the cloud, Byosphere supports collaboration across teams, projects, and geographies and strengthens an organization’s biotherapeutic knowledge and productivity. Customers can also use the same platform in GxP or non-GxP environments.

“We’re thrilled to provide our leading protein analysis solution for enterprise customers, who can now ask deeper questions of their data and use if for advanced analytics,” says Carlson. “We designed Byosphere to integrate easily with existing ELN and LIMS systems and to scale efficiently across one site or many.”

About Protein Metrics

Protein analysis should never be limited by software. With a clear focus on protein characterization, Protein Metrics’ vendor-neutral software allows scientists to use data generated on analytical instruments like mass spectrometers to quickly identify and report protein sequences as well as any variations from the expected form. We innovate so that biopharmaceutical companies and university research labs can achieve confident results from their analysis and reporting. With our customers, we are boldly advancing protein characterization. Protein Metrics is headquartered in Cupertino, CA at the crossroads of computing and biotechnology in the San Francisco Bay Area. For more information, visit http://www.proteinmetrics.com.

Share article on social media or email:

Topelia Therapeutics and InfoBionic Partner in Clinical Trial for COVID-19 Quintuple Therapy


Up to 600 participants in a double-blind, placebo-controlled COVID-19 clinical trial will test the efficacy of a virus treatment.

Patient safety is paramount in all our protocols. Our team understands the importance of the initial EKG screening and continuous remote cardiac monitoring for patients on the prescribed therapy.

Ventura, CA-based Topelia Therapeutics selected InfoBionic as its partner in EKG pre-screening and continuous remote cardiac monitoring services for patients enrolled in their NIH-approved clinical trial Quintuple therapy to treat COVID-19 Infection (HAZDpaC).

This Phase II interventional study will test the efficacy of quintuple therapy (Hydroxychloroquine, Azithromycin, Vitamin C, Vitamin D, and Zinc) for the treatment of patients who test positive for the COVID-19 virus. This is a randomized, double-blind, placebo-controlled study. Individuals included in the clinical trial are treated with this quintuple therapy for 10-days. The study will last 24-weeks with up to 600 participants. Topelia Therapeutics is actively recruiting patients for this study. Visit https:/topeliatherapeutics.com/clinical-trials.

Dr. Sabine Hazan, the clinical trial Principal Investigator stated, “Patient safety is paramount in all our protocols. Our team understands the importance of the initial EKG screening and continuous remote cardiac monitoring for patients on the prescribed therapy.” Further, “Partnering with InfoBionic was made easier when in response to the COVID-19 pandemic, InfoBionic released a new set of features designed specifically to help in monitoring and diagnosing QT prolongation.”

Dr. Hazan has spent more than 2 decades working with the FDA and NIH to bring medicine to new frontiers, she believes there will always be a place for pharmaceutical clinical trials, and hopes to demonstrate that effective, low-cost solutions are available to treat some of today’s most challenging medical conditions.

Cardiology medical expert Dr. Alon Steinberg, the designated Safety and Medical Monitoring physician supporting the trial, was already familiar with the solution and stated, “InfoBionic meets our needs; the device is easy for the patients to use and the advanced full disclosure monitoring and reporting functions ensure patient safety, making this trial and partnership a success.”

Dave MacCutcheon, InfoBionic COO, remarked, “We are excited to be working with the Topelia Therapeutics team on COVID-19 solutions. This trial complements our ReMoteMeTM program that delivers EKG devices directly to patients’ homes, as many are still unable to visit their doctors’ offices due to current quarantine restrictions.”

Topelia Therapeutics and InfoBionic are committed to providing comprehensive, safe, and innovative solutions that further improve the lives of all people during this unprecedented time.

About Topelia Therapeutics

Strategically placed as a genetic sequencing lab, site, CRO, and now sponsor, Topelia Therapeutics has six COVID-19 studies validating testing, prophylaxis, and treatment protocols for the novel coronavirus. For more, visit: https://TopeliaTherapeutics.com

About InfoBionic

InfoBionic is a digital health company transforming the efficiency and economics of ambulatory remote patient monitoring processes by optimizing clinical and real-world utility for the users that need it most – physicians and their patients. The Massachusetts-based team of seasoned entrepreneurs have had successful careers in healthcare, IT, medical devices, and mobile technology, and bring specific expertise in remote monitoring and cardiology. They have seen first-hand the complexities of traditional cardiac arrhythmia detection and monitoring processes and designed the transformative MoMe® Kardia platform to remove the roadblocks hindering faster, more effective diagnosis and decision-making. Frost & Sullivan bestowed the 2019 North American Remote Cardiac Monitoring Technology Leadership Award upon InfoBionic. For more, visit: https://infobionic.com.

Share article on social media or email:

DuPont Animal Nutrition Announces Manufacturing Facility in Wuxi, China


News Image

“We are pleased to add our Animal Nutrition products to the portfolio we support at our Wuxi facility, and offer world-class quality with very local customization to our China customers” said Katariina Rasinmaki, Global Manufacturing & Supply Chain Leader.

DuPont Nutrition & Biosciences announced today the opening of a new Animal Nutrition manufacturing capability in Wuxi, China. The new plant operation will provide the local animal production industry with customized solutions according to DuPont’s global quality standards and advanced technology.

“This facility will improve the flexibility of our offerings to the Chinese animal nutrition market,” said Aart Mateboer, Business Unit Director, Animal Nutrition. “We look forward to providing our key accounts a more customized offering, as well as a larger range of packaging sizes to better meet our customers’ needs. It provides us enhanced capabilities to launch many new products out of our global R&D pipeline to support the evolving needs of our customers in China”.

“We are pleased to add our Animal Nutrition products to the portfolio we support at our Wuxi facility, and offer world-class quality with very local customization to our China customers” said Katariina Rasinmaki, Global Manufacturing & Supply Chain Leader.

“We continue to enhance our capability to deliver solutions from our best in class product portfolio to our Asia Pacific customers”, said Vik Prabhu, Regional Director, Health & Biosciences, Asia Pacific. “We recently expanded our capability at our Shanghai Animal Nutrition Applications & Technical Service Laboratory, which is an excellent complement to this new operation. Due to African Swine Fever and Covid-19, our customers have adapted quickly to changing conditions and this facility is designed to provide flexible local response to our most valued customers”.

DuPont Animal Nutrition is a market leader in nutritional health solutions with a comprehensive portfolio of feed enzymes, betaine, phytogenics and probiotics. Through the lens of nutribiosis, DuPont invests in science and innovation to help producers improve performance, increase liveability and support welfare in the face of increasing pressure to reduce or remove antibiotics from production systems. DuPont Animal Nutrition capabilities are underpinned by the quality and quantity of our trials, including over 80,000 guts sampled from over 500 farms, investments in omics technologies and microbiome research, and collaboration with leading commercial, governmental and academic partners. For more information, visit http://www.animalnutrition.dupont.com

About DuPont Nutrition & Biosciences

DuPont Nutrition & Biosciences applies expert science to advance healthy and sustainable solutions for the food, beverage, dietary supplement and pharmaceutical industries. We also use pioneering biotechnology to enable bio-based solutions that make products and industrial processes more efficient and sustainable. For more information: http://www.dupontnutritionandbiosciences.com.

About DuPont

DuPont (NYSE: DD) is a global innovation leader with technology-based materials, ingredients and solutions that help transform industries and everyday life. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets including electronics, transportation, construction, water, health and wellness, food and worker safety. More information can be found at http://www.dupont.com.

# # #

08/27/2020

DuPont™, the DuPont Oval Logo, and all trademarks and service marks denoted with ™, SM or ® are owned by affiliates of DuPont de Nemours, Inc. unless otherwise noted.

Share article on social media or email:

Streamlining Bioanalytical Assays with Seamless Transfer of SCIEX Analyst™ Data to IDBS E-WorkBook, Upcoming Webinar Hosted by Xtalks


Xtalks Life Science Webinars

The most effective solutions recognize the importance of direct integration of instrumentation with software to establish closed-loop, compliance workflows.

Streamlining processes, ensuring consistency and risk reduction are widely sought objectives in the analytical laboratory. As sample volumes increase against fixed resources, especially in the contract market, service providers often turn to software to enable their people to meet these goals. The most effective solutions recognize the importance of direct integration of instrumentation with software to establish closed-loop, compliance workflows.

With its latest product innovations, IDBS continues to find new ways to help R&D organizations capture, manage, and gain insights from their scientific and operational data. The company is excited to announce the release of a new integration component with SCIEX Analyst™, for both cloud and on-premise platforms of E-WorkBook.

In response to demand for increased compliance and a unified workflow, the integration to SCIEX Analyst™ enables users to export sample lists from E-WorkBook and retrieve results data from Analyst™ with ease.

This integration is part of IDBS’ commitment to improve upon the leading scientific informatics platform in the market. As part of the Danaher Life Science platform, IDBS will continue to deepen its partnership with SCIEX and other operating companies as part of an ongoing initiative to deliver the next-generation biopharmaceutical working environment.

Join Graeme Dennis – Commercial Director, Preclinical Biopharma at IDBS and Ian Peirson – Senior Product Manager at IDBS in a live webinar on Monday, September 14, 2020 at 10am EDT (3pm BST/UK).

For more information or to register for this event, visit Streamlining Bioanalytical Assays with Seamless Transfer of SCIEX Analyst™ Data to IDBS E-WorkBook.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Modality Solutions Makes Inc. 5000 List of America’s Fastest-Growing Companies 2nd Consecutive Year


The Inc. 5000 list represents a unique look at the most successful companies within the American economy’s most dynamic segment–its independent small businesses.

Modality Solutions is pleased to be recognized for the second year in a row,” said President Gary Hutchinson. “Our primary goal is to continue to help clients successfully launch new therapies while we continue on our track record of successful outcomes for our clients.

Modality Solutions, a biopharmaceutical cold chain validation engineering firm, is pleased to announce it made Inc. magazine’s 2020 annual Inc. 5000 list. The list is the most prestigious ranking of the nation’s fastest-growing private companies. Modality Solutions made the Inc. 5000 list in 2019 as well, and for this year’s list, reported three-year revenue growth of 71 percent.

The Inc. 5000 list represents a unique look at the most successful companies within the American economy’s most dynamic segment–its independent small businesses. The Houston-based firm was one of four engineering firms from the metro area and one of 11 in the State of Texas.

In addition to the recognition by Inc. magazine this year, the firm’s quality management system was ISO 9001:2015 certified. The certification covers consulting, design and engineering services and testing for supply chain logistics related to transport-sensitive food and drug products.

Co-founded in 2011 by Gary Hutchinson and Daniel J. Littlefield, Modality Solutions is a global biopharmaceutical cold chain validation engineering firm. It supports fast-track regulatory approval for biologics and specialty therapies. As industry logistics network experts, it provides engineering services focused on the qualification of thermal packaging, the selection of monitoring & controls systems, the execution of transport validation, the design of controlled-environment logistics, and the operational support for clinical trials.

“Modality Solutions is pleased to be recognized for the second year in a row within the American economy’s most dynamic segment—its independent small businesses,” said President Gary Hutchinson. “Our primary goal is to continue to help clients successfully launch new therapies while we continue on our track record of successful outcomes for our clients. It’s great to join the ranks of companies like Intuit, Zappos, Under Armour, Microsoft, Patagonia, and many other well-known brands that gained their first national exposure as honorees on the Inc. 5000.”

Since 1982, the Inc. 5000 list has become the hallmark of entrepreneurial success. For 2020, companies were ranked according to percentage revenue growth when comparing 2016 and 2019. Companies had to be U.S.-based, privately held, for-profit, and independent and have been founded and generating revenue by March 31, 2016. The minimum revenue required for 2016 was $100,000; the minimum for 2019 was $2 million.

“The companies on this year’s Inc. 5000 come from nearly every realm of business,” says Inc. editor-in-chief Scott Omelianuk. “From health and software to media and hospitality, the 2020 list proves that no matter the sector, incredible growth is based on the foundations of tenacity and opportunism.”

To view Modality Solutions Inc. 5000 and Inc. Verified Profile online page, visit https://www.inc.com/profile/modality-solutions.

To learn more about Modality Solutions, visit its website at https://www.modality-solutions.com.

For more information on Inc. and the Inc. 5000 Conference, visit https://conference.inc.com.

About Modality Solutions, LLC

Founded in 2011, Modality Solutions, a leading biopharmaceutical cold chain validation engineering firm, specializes in integrating cold chain operations, developing transport validation strategies, supporting global regulatory applications, and global clinical trial operations. By combining the best practices of process validation, systems qualification, and risk assessment, Modality Solutions has earned the reputation of ensuring regulatory compliance, drug product quality, and patient safety. As a 2019 and 2020 Inc. 5000 company, Houston Business Journal Fast 100, Entrepreneur 360™, and Forbes Technology Council company, Modality Solutions’ team of engineers are experts at delivering cold chain thermal packaging design and qualification, conducting transport simulation testing with its Advantage Transport Simulation Laboratory™, and designing controlled environment-logistics solutions. For more information, visit https://www.modality-solutions.com.

Share article on social media or email:

LRC Systems Receives Grant Award from the Gordon and Betty Moore Foundation


News Image

Collaborating with these brilliant teams will foster new ideas and principles that could push the aquatic symbiosis field years ahead.

Today, Laboratory for Research in Complex Systems (LRC), announced it has been awarded a grant to join 41 other international scientific teams working collaboratively on The Gordon and Betty Moore Foundation’s Symbiosis in Aquatic Systems Initiative. The Moore Foundation fosters path-breaking scientific discovery, environmental conservation, patient care improvements and preservation of the special character of the Bay Area. The funding will provide the scientific community with new tools and laboratory techniques to develop new model systems and capabilities in the understanding of aquatic symbioses.

Symbiosis is a phenomenon where two organisms live in a tight physical association and benefit from each other. Such associations not only are thought to be at the origin of complex life, they also continue to keep shaping it by playing a central role in the ecology and evolution of present-day species. Scientists at LRC aim to gain a better understanding of one particular type of symbiosis – chemosynthetic symbiosis – where microbes or animals harness the power of chemosynthetic bacteria that are capable of producing organic compounds in the dark. Discovered in the deep sea in the ‘70s, chemosynthetic symbioses are ubiquitous on Earth. Despite their common occurrence, however, lack of good model systems to design experiments and test hypotheses have hampered efforts to better understand the process and the exciting biology behind these associations.

With this grant, LRC will receive support to pursue ambitious research aimed at conceptual and methodological advances in symbiotic systems where the same symbiont is associated with different hosts. “The Moore Foundation’s commitment to blending leaders in aquatic symbiosis research with scientists from other areas for sharing perspectives and fostering integrative brainstorming echoes LRC’s mission to serve as an ideas hub for high-level transdisciplinary research to propel innovations that can change the world,” said Dr. Shailesh Date, founder CEO of LRC Systems. “Collaborating with these brilliant teams will foster new ideas and principles that could push the aquatic symbiosis field years ahead.”

Aquatic environments are Earth’s largest natural habitat with evolutionary processes continuously underway. A significant portion of Earth’s biodiversity lives in marine and freshwater ecosystems with much of this unexplored. Understanding the biological interdependence of organisms within these aquatic environments provides critical insight into their evolution and role in ecological systems. The Symbiosis in Aquatic Systems Initiative will provide learnings on the role symbiotic interactions play in the larger world’s evolution and function.

For more information about the LRC team and its role in the Symbiosis in Aquatic Systems Initiative, visit https://www.lrc.systems.

To learn about the Moore Foundation’s Symbiosis in Aquatic Systems Initiative, visit https://www.moore.org/article-detail?newsUrlName=building-community-to-accelerate-the-pace-of-model-system-development-in-aquatic-symbiosis.

About LRC Systems

Laboratory for Research in Complex Systems (LRC) develops powerful research-based solutions that drive scientific, commercial and social breakthroughs. Led by a team of trailblazers from industry and academia, LRC uniquely combines advances in natural and quantitative sciences with cutting-edge technology to help solve fundamental health, economic and social problems for public and private organizations. LRC serves as an ideas hub for high-level transdisciplinary research that is bigger, faster and more impactful, to propel innovations that can change the world.

Share article on social media or email:

Sentien Biotechnologies Announces Open IND in Phase 1/2 Trial of SBI-101 for Patients with COVID-19


News Image

Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) application for the evaluation of Sentien’s lead asset, SBI-101, for the treatment of severe COVID-19. Approval of this IND allows Sentien to initiate a Phase 1/2 study with a focus on COVID-19 patients suffering from both acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI) requiring renal replacement therapy (RRT).

SBI-101 is a combination product that integrates allogeneic mesenchymal stromal cells (MSCs) within an extracorporeal, blood-filtration device. MSCs are a unique source of therapeutic secreted factors that modulate the immune-mediated inflammatory response to acute organ injury. By keeping the MSCs confined within a blood-filtration device, SBI-101 enables controlled, dynamic, and sustained delivery of MSC-secreted factors to the patient’s blood, without the need for direct injection of the MSCs themselves. SBI-101 integrates into a standard blood circuit such as used with renal replacement therapy, thereby providing patients with both standard-of-care and MSC-mediated blood conditioning in a single session.

“There is a compelling scientific rationale for studying SBI-101’s effect on COVID-19. SBI-101 is designed to restore balance to a dysregulated immune system; we believe this design is well suited to calm the hyperinflammatory cytokine storm associated with severe COVID-19 patients,” said Sentien Chief Medical Officer, Allen R. Nissenson, MD.

“COVID-19 is a very logical application for SBI-101,” said Sentien CEO, Brian Miller. “Our previous study of SBI-101 in subjects with dialysis-requiring AKI showed preliminary evidence of anti-inflammatory effects consistent with the SBI-101 therapeutic hypothesis. We are fortunate to have been well-positioned to now focus our attention on COVID-19 patients, who obviously have an urgent need for therapeutics.”

“We are excited to have clearance from FDA to initiate this study of SBI-101 in the COVID-19 patient population,” said Sentien Executive Chairman, Richard Ganz. “Sentien’s mission has always been to develop cell therapies to address diseases characterized by systemic inflammation. The emergence of COVID-19 has served to strengthen our mission even more.”

The multi-center trial is a randomized, controlled, ascending dose Phase 1/2 study in patients with COVID-19 requiring RRT. The primary objective of the trial is to evaluate the safety and tolerability of SBI-101; endpoints for efficacy and pharmacodynamic responses to SBI-101 therapy will also be evaluated.

Please visit https://clinicaltrials.gov/ct2/show/NCT04445220 for more information about the study.

About Sentien Biotechnologies

Sentien Biotechnologies, Inc. is a privately-held, clinical-stage company developing novel ex-vivo cell therapy applications to treat conditions caused by systemic, immune-mediated inflammation. Sentien’s lead product, SBI-101, integrates allogeneic mesenchymal stromal cells (MSCs) within an extracorporeal, hollow-fiber device. By immobilizing MSCs within a blood-filtration device, SBI-101 enables controlled, dynamic, and sustained delivery of MSC-secreted factors to the patient’s blood, without the need for direct injection of the MSCs themselves.

SBI-101 has been evaluated in a Phase 1b/2a study in subjects with dialysis-requiring acute kidney injury (AKI-D). An initial readout from the study provides preliminary evidence of anti-inflammatory and wound healing effects consistent with the SBI-101 therapeutic hypothesis. Building on this data, SBI-101 is being investigated in COVID-19 patients suffering from severe systemic inflammation.

Sentien’s technology can be applied to additional systemic inflammatory indications in both acute and chronic diseases, focusing on complex conditions where single-factor agents have not been effective.

For more information, please visit http://www.sentienbiotech.com.

Share article on social media or email:

JAIN Irrigation hires industry veteran Dave Laybourn as Enterprise Sales Manager for its ETwater smart irrigation subsidiary


Laybourn brings more than 20 years’ experience in commercial, industrial, agriculture and landscaping sales to focus on development of the enterprise strategy, along with managing the Fortune 500 customers of ETwater.

“We’re excited to have Dave join our team and lead our Enterprise Sales activities,” said Andy Belingheri, National Sales Manager at Jain Irrigation, Inc. “His caliber of success and experience are ideally suited for selling the most innovative, technologically advanced intelligent, smart irrigation control system worldwide. Under Dave’s leadership we look forward to helping many more businesses conserve water, reduce expenditures and improve their corporate sustainability.”

Richard Restuccia, V.P. of Water Management Solutions is excited about Dave joining the team and growth at Jain Irrigation Inc. “Jain Irrigation is in growth mode right now and additions like Dave Laybourn are great for the company. Jain feels a deep sense of responsibility to develop products and educate customers to manage water responsibly. Dave brings a wealth of irrigation knowledge plus a passion for sustainability and water management, three of our most important initiatives.”

Before joining Jain Irrigation, Laybourn was at Olson Irrigation where he was responsible for the go-to-market of an automatic self-cleaning water filter for agriculture. Prior to Olson, he worked at Rain Bird in field sales and product management that included being named on two U.S. patents for drip irrigation. “Agriculture is where I learned about ET (evapotranspiration) and how valuable it is, not only for saving water but also for the best plant health,” said Laybourn. “I look forward to sharing this and other insights with the Enterprise about ETwater technology, which should be their basis for making investments in smart irrigation that deliver financial payback and a return on investment that is often much better than the owner’s core business.” Dave Laybourn has a Bachelor of Science in Mechanical Engineering from Stanford University.

ABOUT JAIN IRRIGATION

Jain is a fully integrated global food/plant production company recognized by Harvard Business to be one of five global sustainability champions and the G-20 for lifting people out of poverty. Our irrigation manufacturing capabilities include everything from behind the pump to the flush valve at the end of the lateral and everything in between including drip irrigation. We lead the industry in manufacturing technology, owning both our extrusion and mold manufacturing equipment providers. Jain leads plant science research globally across a variety of food crops and is staffed with some of the world’s leading research scientists. With the Gandhi Library, Jain now houses the prominent collection of the world’s best plant science knowledge in a single facility. Our agronomic knowledge is integrated from our world-class tissue culture operations through our food processing businesses. We research, educate, advance, manufacture, finance, propagate plants, and purchase produce for processing all to fulfill the Jain mission, “leave this world better than you found it.”

Share article on social media or email:

UMD Researchers Discover a New Role for a Well-Known Molecule as a Plant Hormone, with Implications for Seed Production and Crop Yield


ACC facilitates fertilization. Pollen tubes (stained blue) fertilize only some ovules in the presence of less ACC. Successful fertilization, blue dots inside white ovules. Credit, Dr. Wangshu Mou.

ACC facilitates fertilization. Pollen tubes (stained blue) fertilize only some ovules in the presence of less ACC. Successful fertilization, blue dots inside white ovules. Credit, Dr. Wangshu Mou.

“[This paper] introduces a new plant growth regulator or plant hormone, alongside a small handful of other publications. It isn’t a newly identified molecule, but it has never been thought of before as a plant hormone, only as the precursor to ethylene,” says Caren Chang, UMD.

Researchers at the University of Maryland (UMD) have discovered an entirely new role for a well-known plant molecule called ACC, providing the first clear example of ACC acting on its own as a likely plant hormone. Just like in humans and animals, hormones in plants carry messages to signal and trigger essential processes for plant health and functionality, from reproduction to defense. Without these processes, crops can’t reproduce and thrive to provide the food we need to feed a growing global population. In a new publication in Nature Communications, researchers show that ACC has a critical role in pollination and seed production by activating proteins similar to those involved in nervous system responses in humans and animals. These findings could not only change textbooks that have previously attributed plant responses to the hormone ethylene instead of ACC, but could also open the door for new research to improve plant health and crop yield.

“There are several novel things about this paper,” explains Caren Chang, UMD. “But the main impact is that it introduces a new plant growth regulator or plant hormone, alongside a small handful of other publications. It isn’t a newly identified molecule, but it has never been thought of before as a plant hormone, only as the precursor to ethylene.”

Chang, a professor in Cell Biology & Molecular Genetics and affiliate professor of Plant Science & Landscape Architecture supported by the Maryland Agricultural Experiment Station (MAES), explains that ethylene is one of the five major plant hormones and has been studied for over a century. It is important for many processes that are vital to plant health and crop production, including fruit ripening, stress responses to flooding and drought, plant disease defenses, germination, and flowering.

“In much of the research, ACC has been used in place of ethylene, knowing that it’s a precursor that plants convert into ethylene. This is because ACC is easy to work with in powder form and can even be sprayed on the plant, but working with ethylene is very difficult because it is a gas. So researchers have used ACC for decades in place of ethylene, and the literature would interpret the observed responses as ethylene responses. What our paper shows is that an ACC response is not necessarily an ethylene response. While ethylene is an important plant hormone with its own set of functions, some of these responses that have been attributed to ethylene through ACC may actually be separate ACC responses, acting as a growth regulator or hormone itself.”

This finding opens the door for many papers across decades of research, as well as textbooks and future education on plant hormone responses, to be revised in the event that ACC is actually triggering important plant processes previously attributed to ethylene.

According to Chang, the paper also presents advances in plant reproduction. “In the plant reproduction field, there are many steps that are critical in pollination, and one of these steps requires the pollen to reach the ovules to actually produce a seed,” says Chang. “Our paper shows that ACC signaling in the ovule is involved in getting the pollen tube to turn and effectively deliver the pollen, which makes it essential for seed production. It’s probably the first example showing how the maternal ovule tissue actually helps attract the pollen tube.” And this isn’t a small effect, Chang stresses. “The seed number pretty much doubles in the presence of ACC. There is potential here to improve the seed number, which can increase food production in certain crops and have an impact on food security long-term.”

Led by José Feijó, another professor in Cell Biology & Molecular Genetics and affiliate professor of Plant Science & Landscape Architecture, another major finding of this paper shows clear connections between human, animal, and plant hormone signaling pathways by identifying a potential receptor for ACC activity.

“The most interesting parallel is cell-cell communication,” explains Feijó. “Animal glutamate receptors are proteins which are needed for information to jump from one neuron to the next, either through an electric impulse or through calcium signaling, which is essential for things like memory. Problems in the processes mediated by glutamate receptors are known to be related to neurodegeneration and depression.”

Chang adds, “These receptors have been found in the human nervous system, and neuroscientists have been studying them for drug development to treat nervous system issues like depression. They found that ACC can actually affect the nervous system in humans. So we decided to look for the same receptors, named glutamate-like receptors (GLRs) in plants, to see if they respond to ACC in plants. We found that ACC can actually affect GLRs in plants as well.”

This finding opens an entirely new avenue of research in plant biology and points to similarities in plants and humans that are currently not well understood. “In plants, GLRs all seem to convey functions related to communication, either to bring male and female genes into an egg, or in pathogen or stress alert systems and defenses,” says Feijó. “Emerging trends suggest that GLRs underlie long distance electric signaling through the plant vascular system, where injury to tissues in one leaf inform the whole plant to create nasty substances to deter insects. All these lines seem to point into the existence of electric communication within plant tissues and organs, and that these functions involve GLRs. This is an interesting parallel evolution of a function for glutamate receptors as they evolved to be associated with the animal nervous systems to perform similar functions.”

With ACC as a new candidate activating GLRs and all the newly discovered roles it is playing as a plant hormone, Chang and the team are excited about the directions this work can go. “There is still a lot of research to be done to see how this is all happening and can be used in different crops, but all that new research can happen now.”

This paper, entitled “Ethylene-independent signaling by the ethylene precursor ACC in Arabidopsis ovular pollen tube attraction,” is published in Nature Communications, DOI: 10.1038/s41467-020-17819-9.

Share article on social media or email:

EMMA International Consulting Group, Inc. Welcomes Jeff LaFave as Their New Vice President of Sales and Business Development


News Image

“I’m thrilled to join the EMMA International team and look forward to helping many clients with their regulatory and compliance needs. I think there is value in what EMMA International is doing in the industry and I am excited to help the company grow,” said Jeff LaFave

E.M.M.A. International Consulting Group, Inc. (EMMA International), a global leader in FDA compliance consulting, welcomes Jeff LaFave as their Vice President of Sales and Business Development to lead the company’s domestic and international sales efforts.

Mr. LaFave has been a life sciences industry sales/business development executive for 40 years. With a background in diversified biologics and medical device firms, Mr. LaFave has worked for such firms as Boehringer Mannheim Diagnostics, Cepheid and Zoetis representing many cutting-edge technologies including Hybrid Capture for the detection of HPV (Cervical Cancer) and PCR (Infectious Disease, COVID19). His breadth of product experience and oversight spans products including durable equipment, diagnostics and disposable devices; pharmaceutical products including solutions, parenterals, biologics and combination products.

“I am pleased to welcome Jeff LaFave to the EMMA International team,” said Dr. Carmine Jabri, EMMA International’s President. “Jeff brings a wealth of industry knowledge and experience across various aspects of the medical device, diagnostics, pharmaceutical and biotechnology business arenas. Jeff has both the sales and the business development expertise that will enable our firm to further our current collaborative relationships, develop new business opportunities, and expand business growth for the Company.”

“I’m thrilled to join the EMMA International team and look forward to helping many clients with their regulatory and compliance needs. I’ve been through that frustration on the industry side and I think there is real reward and value in what EMMA International is doing in the industry and I am excited to help the company grow,” said Jeff LaFave.

Through his leadership, Mr. LaFave has been enthusiastic about inspiring diverse global organizations to achieve common goals while consistently delivering material value at every level. He holds a Bachelor of Science in Marketing from Central Michigan University.    

About EMMA International

EMMA International Consulting Group, Inc. is a global leader in FDA compliance consulting, with headquarters in Bingham Farms, MI. We focus on quality, regulatory, and compliance services for the biotechnology, pharmaceuticals, and medical device industries.

EMMA International is certified to ISO 9001:2015, a globally recognized quality management standard developed by the International Organization for Standardization (ISO).

EMMA International is certified as a Women’s Business Enterprise (WBE) through the Women’s Business Enterprise National Council (WBENC), the nation’s largest third-party certifier of businesses owned and operated by women in the US.

For more information, visit http://www.emmainternational.com/

If you would like additional information, please contact Katie McCallum, Marketing and Operations Specialist at 248-987-4497 or email at Katie.mccallum@emmainternational.com.

Share article on social media or email: